The potato proteinase inhibitor 11 promoter was studied to identify cis-acting regulatory sequences involved in methyl jasmonate (MJ) response using transgenic tobacco plants carrying various lengths of the promoter fused to a chloramphenicol acetyltransferase reporter gene. An intemal fragment between -625 and -520 was sufficient to confer a response to MJ, wounding, or sucrose when it was placed upstream of the nos promoter -101, which contains the CAAT-TATA region. Deletion of the proteinase inhibitor 11 promoter sequence upstream of -611 did not affect the MJ response, but a further deletion to -573 eliminated the response. The 3'-deletion study showed that the DNA sequence downstream from -520 is dispensable. However, 3'-deletion mutant -574 did not respond to the MJ treatment. These results indicated that an element essential for the MJ response is located at the -574/-573 region where the G-box sequence (CACGTGG) is located. The G-box sequence was not required for the sucrose enhancer effect, suggesting that the MJ response mechanism is different from that of sucrose.JA2 and MJ occur commonly in the plant kingdom (4,32,34). These chemicals are synthesized in plants from linolenic acid by an oxidative pathway (4,28,33). It has been proposed that these compounds function as phytohormones because JA and its methyl ester alter the growth of plant tissues (4) and induce senescence (32). Recently, JA and MJ were shown to influence expression of several plant genes. For example,

Patients with disabilities have difficulties tolerating in-office dental treatment due to limitations relating to cooperation and/or physical problems. Therefore, they often require general anesthesia or sedation to facilitate safe treatment. When deciding on dental treatment under general anesthesia, the plan should be carefully determined because compared to general patients, patients with disabilities are more likely to experience anesthetic complications because of their underlying medical conditions and potential drug interactions. Clinicians prefer simpler and more aggressive dental treatment procedures, such as extraction, since patients with impairment have difficulty maintaining oral hygiene, resulting in a high incidence of recurrent caries or restorative failures. This study aimed to review the available literature and discuss what dentists and anesthesiologists should consider when providing dental treatment to patients with severe disability under general anesthesia.

Background Patients with disabilities often require general anesthesia for dental treatment because of their cooperative or physical problems. Since most patients with disabilities take central nervous system drugs, the management of recovery status is important because of drug interactions with anesthetics. Methods The anesthesia records of patients under general anesthesia for dental treatment were reviewed, and data were collected. Healthy patients under general anesthesia for dental phobia or severe gagging reflex were designated as the control group. Patients with disabilities were divided into two groups: those not taking any medication and those taking antiepileptic medications. The awakening time was evaluated in 354 patients who underwent dental treatment under general anesthesia (92 healthy patients, 183 patients with disabilities, and 79 patients with disabilities taking an antiepileptic drug). Based on the data recorded in anesthesia records, the awakening time was calculated, and statistical processes were used to determine the factors affecting awakening time. Results Significant differences in awakening time were found among the three groups. The awakening time from anesthesia in patients with disabilities (13.09 ± 5.83 min) (P < 0.0001) and patients taking antiepileptic drugs (18.18 ± 7.81 min) (P < 0.0001) were significantly longer than in healthy patients (10.29 ± 4.87 min). Conclusion The awakening time from general anesthesia is affected by the disability status and use of antiepileptic drugs.

No abstract